In vitro-in vivo correlation and comparative bioavailability of vincamine in prolonged-release preparations

Drug Development and Industrial Pharmacy

Volumn 26, Issue 3, 2000, Pages 243-251

  Emara, L H ^a   El Menshawi, B S ^a   Estefan, M Y ^a  

^a NATIONAL RESEARCH CENTRE   (Egypt)

Author keywords

Bioavailability; Dissolution; In vitro in vivo correlation; Vincamine

Indexed keywords

DEPOTVINC; OXYBRAL; UNCLASSIFIED DRUG; VINCAMINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; CROSSOVER PROCEDURE; DISSOLUTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; MEAN RESIDENCE TIME; NORMAL HUMAN; PH; RANDOMIZED CONTROLLED TRIAL; SUSTAINED RELEASE PREPARATION;

ADULT; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL AVAILABILITY; DELAYED-ACTION PREPARATIONS; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; REGRESSION ANALYSIS; VINCAMINE;

EID: 0034077064     PISSN: 03639045     EISSN: None     Source Type: Journal    
DOI: 10.1081/DDC-100100352     Document Type: Article

References (24)

1. L. Shargel and A. Tu (Eds.), Pharmacokinetics of drug absorption, in Applied Biopharmaceutics and Pharmacokinetics, 2nd ed., Appleton-Century-Crofts, Norwalk, CT, 1985, pp. 105-129.
2. H. Moeller, F. Langenbuchr, P. Porges, H. Stricker, and G. Tucker, Pharm. Ind., 46, 941-943 (1984).
3. J. P. Skelley, G. L. Amidon, W. H. Barr, L. Z. Benet, J. E. Carter, J. R. Robinson, V. P. Shah, and A. Yacobi, J. Pharm. Sci., 79, 849-854 (1990).
4. S. S. Hwang, W. Bayne, and F. Theeuwes, J. Pharm. Sci., 82, 1145-1150 (1993).
5. J. P. Skelly and G. F. Shiu, Eur. J. Drug Metab. Pharmacokinet., 18, 121-129 (1993).
6. H. J. Malinowski, Proc. Int. Symp. Controlled Release Bioactive Mater., 23, 151 (1996).
7. U. V. Banaker (Ed.), Pharmaceutical Dissolution Testing, Marcel Dekker, New York, 1992, pp. 53-107.
8. F. Langenbucher, J. Pharm. Sci., 58, 1265 (1969).
9. U.S. Pharmacopeial Convention, The United States Pharmacopeia 23/National Formulary 18, Author, Rockville, MD, 1995.
10. P. Buri, E. Doelker, and J. Boucherat, J. Clin. Hosp. Pharm., 6, 101-105 (1981).
11. M. Specker, K. Weihgold, J. Kappler, and A. Klimke, Dtsch. Apoth.-Ztg., 118(1), 1-4 (1978).
12. K. Weihgold, M. Specke, and F. Leuschner, Therapiewoche, 28(23), 4709-4714 (1978).
13. P. A. Sado, D. Gibassier, and R. Leverge, Expo. Congr. Int. Technol. Pharm., 3, 221-232 (1985).
14. D. Steinbach, E. Weber, W. Stueber, H. Moeller, and C. Piper, Pharm. Ztg., 125(7), 351-360 (1980)
15. WHO, Interchangeable multi-source pharmaceutical products, Drug Information, 8(2) (1994).
16. H. H. Blume and K. K. Midha, Bio-International 2, Medpharm Scientific, Stuttgart, 1995.
17. L. Dal Bo, C. Giovanna, and B. Giampietro, J. Chromatogr., 573, 158-162 (1992).
18. M. Gibaldi and D. Perrier, Pharmacokinetics, Marcel Dekker, New York, 1982, pp. 409-416.
19. K. Ventouras, J. Boucherat, and P. Buri, Pharm. Acta Helv., 52, 119-123 (1977).
20. J.-M. Aiache, M.-C. Delatte, P.-P. Leblanc, J.-P. Kantelip, R. Gomeni, and J.-L. Steimer, Biopharm. Drug Dispos., 11, 279-309 (1990).
21. P. S. Banerjee and J. R. Robinson, Clin. Pharmacokinet., 20, 1-14 (1991).
22. J. P. Skelley, G. L. Amidon, W. H. Barr, L. Z. Benet, J. E. Carter, J. R. Robinson, V. P. Shah, and A. Tacobi, J. Pharm. Sci., 79, 849-854 (1990).
23. A. Frick, H. Moeller, and E. Wirbitzki, Eur. J. Pharm. Biopharm., 46, 313-319 (1998).
24. FDA, Guidance for Industry, Extended release oral dosage forms: development, evaluation, and application for in vitro/in vivo correlations, Dissol. Technol., 11, 23-31 (1997).